HemoBioTech, Inc. (OTC BB: HMBT)

HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company, is focused on developing HemoTech™, which may be the first viable substitute for human blood. HemoTech™, the company’s core product, is a bovine-hemoglobin (Hb) based human blood substitute that has the capability of replacing red blood cells in the human body. The company has an exclusive worldwide license for HemoTech, and intends to use its technology to meet the increasing demand for safe and inexpensive human blood substitute product around the world. For further information, visit the Company’s web site at www.hemobiotech.com.